SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

American Battery Technology Co. is a technology company, which engages in the development and marketing of lithium-ion batteries. Its projects include recycling plant, United States Advanced Battery Consortium (USABC), and Tonopah flats. The company was founded on October 6, 2011 and is headquartered in Reno, NV.

American Battery Technology Company

American Battery Technology Company ($ABAT) is trending as investors discuss the stock's recent surge and subsequent pullback, with some citing a potential short attack on the sector. The community is weighing the possibility of a share offering and dilution against the company's long-term potential and upcoming milestones. Some traders express frustration, while long-term holders remain confident, viewing dips as buying opportunities.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending as cannabis stocks experience heightened volatility, with a trading halt adding to the speculation. Community members are pointing to Doug Kass naming MSOS his trade of the month and are awaiting sector-wide news, possibly related to rescheduling efforts, to explain the sudden surge. Some investors believe any announcements could tie into Veterans Day, while others expect action to be delayed.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending as traders discuss a recent pullback after a significant run-up, with some viewing it as a buying opportunity amid ongoing conversation around government contracts and the company's position in the antimony market. Community members are debating entry points, expressing both excitement and caution, while also considering the broader sector dynamics. There is also discussion about UAMY's expansion and potential impact on future earnings.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending amidst volatile trading, with community members debating its valuation and potential for future growth in the quantum computing sector. Some traders point to insider selling and a lack of current revenue as reasons for caution, while others highlight the potential of quantum computing and recent contracts as bullish signals. Discussions also include comparisons to other quantum computing companies and broader market conditions.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

OMER is trending as the community anticipates potential approval and commercialization of narsoplimab, with discussions centering on upcoming labeling discussions and potential partnership agreements. The asset purchase and license agreement with Novo Nordisk for zaltenibart is seen as a positive catalyst. Some traders are closely watching for a short squeeze, and several analysts have recently issued buy ratings with significantly increased price targets.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ ($LAES) is trending due to a recent offering priced at $7.50 per share, which the community sees as a sign of institutional confidence despite potential dilution. Investors are actively discussing the company's upcoming catalysts, including the IQT Quantum +AI summit and potential government contracts, while weighing the impacts of the offering on short-term price action. The stock's connection to the growing quantum computing sector and strategic partnerships are also driving interest.

NioCorp Developments Ltd. engages in the evaluation, acquisition, exploration, and development of mineral deposits. It focuses on a super alloy materials project in Nebraska for producing niobium, scandium, and titanium. The company was founded on February 27, 1987, and is headquartered in Centennial, CO.

NioCorp Developments Ltd

NioCorp is trending due to growing excitement around potential government funding and rising demand for critical minerals amid increasing geopolitical tensions with China. The community is actively discussing upcoming drill results, loan approvals, and the company's strategic positioning in the U.S. supply chain, with many seeing it as a key player in the rare earth sector.

Sadot Group, Inc. operates as a restaurant chain business. It operates through the following segments: Muscle Maker Grill Restaurant, Pokemoto Hawaiian Poke Restaurant, Non-Traditional (Hybrid), SuperFit Foods Meal Prep, and Sadot. The firm offers protein- based meals featuring chicken, seafood, pasta, hamburgers, wraps and flat breads. It also provides salads, protein shakes and fruit smoothies. The company was founded by Rodney C. Silva in 2022 and is headquartered in Burleson, TX.

Sadot Group Inc

SDOT is trending due to speculation surrounding potential benefits from recent comments regarding cooking oil supply chains, sparking high volatility and chatter around its low float. Community members are actively discussing potential price targets and the possibility of a short squeeze. Some traders are pointing to the company's strong revenue and potential value, while others express skepticism.

HCM II Acquisition Corp. operates as a blank check company. It was formed for the purpose of entering into a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on April 4, 2024 and is headquartered in Stamford, CT.

HCM II Acquisition Corp - Ordinary Shares - Class A

HCM II Acquisition Corp.

HCM II Acquisition Corp. ($HOND) is trending due to its upcoming merger with Terrestrial Energy, a molten salt reactor developer, scheduled for a shareholder vote on October 20th. The community is discussing its potential as a nuclear energy play, drawing comparisons to $OKLO and anticipating significant gains post-merger. Some investors believe $HOND is undervalued relative to its peers and are buying the dip, while others are wary of a potential sell-off after the merger.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels is experiencing a pullback, sparking community debate on whether it's a buying opportunity or the start of a decline after a significant year-to-date surge linked to increased rare earth production and potential government support. Community members are weighing profit-taking against the company's strong position in the rare earth and uranium sectors, anticipating further upside amid growing demand for these resources in AI and defense.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Albert Invent Partners with Kenvue to Build the Future of Consumer Health Products With the Help of AI

Frontier AI company Albert Invent today announced a strategic partnership with Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Zyrtec, Neutrogena, and Listerine, to accelerate...

Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know

J&J gears up for Q3 results with solid gains from Darzalex, Tremfya and MedTech, even as Stelara faces fierce biosimilar pressure.

Families are asking a U.S. appeals court to revive lawsuits against Kenvue and retailers that sold acetaminophen, alleging Tylenol and generic versions of the drug caused autism and ADHD in children, and pointed to U.S. President Donald Trump’s recent advice that pregnant women avoid the pain reliever.<a href="https://stocktwits.com/symbol/KVUE">Shares of Kenvue</a> closed Wednesday down 2.2% at $16.86, before edging up 0.8% in after-hours trading.Lawyer Ashley Keller, representing the families, notified the 2nd U.S. Circuit Court of Appeals on Wednesday of the administration’s position, according to a Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/legal/government/attorneys-urge-court-overseeing-tylenol-autism-lawsuits-consider-trump-2025-09-25/">report</a>.At a White House press event two days earlier, Trump, along with FDA Commissioner Marty Makary and Health Secretary Robert F. Kennedy Jr., highlighted research by Harvard public health dean Andrea Baccarelli, one of the plaintiffs’ experts.More than 500 lawsuits against Kenvue and retailers were dismissed last year by U.S. District Judge Denise Cote in Manhattan, who concluded the expert testimony lacked reliable methods and relied on selective analysis. The appeals court is scheduled to hear arguments on Oct. 6.Kenvue said regulators have not confirmed any link between acetaminophen and autism, adding that it expects the litigation to fail. Legal experts said it would be unusual for the appeals court to give much weight to the administration’s actions or Trump’s comments in deciding how to proceed with the cases.Separately, South Korea’s drug regulator said it would seek information from companies following Trump’s remarks, though it added the U.S. announcement “contained little substance.” The FDA also said it would not ban acetaminophen but will add a pregnancy-related autism warning to labels while stressing no causal link has been proven.Studies have shown conflicting results. A 2024 Swedish study involving 2.5 million children found no causal connection, while a 2025 review of 46 prior studies, co-authored by Baccarelli and colleagues from Mount Sinai and Harvard, suggested a potential association but stated that causation could not be proven.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 186% jump in 24-hour message volume.“I’d guess pregnant women make up a small portion of total Tylenol consumption,” said one user. “Great opportunity to buy at a discount. Will get paid the dividend while the market takes its time to think about this one.”<stembedurl>https://stocktwits.com/wildwood10/message/629884537</stembedurl>Another user reported buying shares at $16.63 for a long-term dividend portfolio and was watching to see if the price dropped further or if that day marked the low.<stembedurl>https://stocktwits.com/Sir_White/message/629891850</stembedurl>Kenvue’s stock has declined 18.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Kenvue logo is seen displayed on a smartphone screen. U.S. health officials will hold a press conference on autism, which is expected to link Kenvue's Tylenol to the disease. (Illustration by Thomas Fuller/Getty Images)

Kenvue Stock To Face More Headwinds? Trump’s Tylenol Warning Revives Autism Lawsuits, Retail Bulls Stay Unfazed

More than 500 lawsuits over Tylenol and autism were dismissed last year, but families are now appealing to the 2nd U.S. Circuit Court of Appeals, which is scheduled to hear arguments on Oct. 6.

Equity

Kenvue shares traded 2.5% higher in premarket on Wednesday as investors took comfort from reassurances by global health agencies that Tylenol remains safe, with no new evidence linking its use in pregnancy to autism.&nbsp;South Korea’s drug regulator said it would seek information from companies after U.S. President Donald Trump’s comments linking Tylenol to autism.&nbsp;"Since the U.S. government’s announcement contained little substance, we have no additional comments," Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/south-koreas-drug-watchdog-review-us-tylenol-claim-2025-09-24/">reported</a>, citing South Korea's food and drug safety ministry.The news follows a rebound on Tuesday when Kenvue rose 1.6% in regular trade and another 0.8% after hours. That rally came after the U.S. Food and Drug Administration stopped short of banning acetaminophen and instead announced it will add a pregnancy-related autism warning to product labels while alerting physicians nationwide. The FDA noted that no causal link has been established between the two.Despite the FDA’s caution, plaintiffs’ lawyers said the label change could revive litigation that was dismissed by a federal court last December. Citi said the legal risks appear to be limited, while Evercore ISI cut its price target to $18. Barclays said the recent selloff looks overdone even in the unlikely event of U.S. acetaminophen sales being reduced to zero.Kenvue, led by interim CEO Kirk Perry, is already facing slowing sales, pressure from activist investors, and a review of its brand portfolio that could result in divestitures of its smaller skincare lines.&nbsp;Tylenol remains its largest brand and contributes a mid-to-high single-digit share of revenue. Analysts warn the FDA’s move could erode consumer trust and weigh on demand, especially among pregnant women, while also creating confusion for patients who need fever treatment during pregnancy.The situation is being described as Kenvue’s most serious reputational challenge since the Tylenol cyanide poisonings of the 1980s.On Stocktwits, retail sentiment for Kenvue was ‘bullish’&nbsp;heading into Wednesday’s session, following a 270% surge in 24-hour message volume.<a href="https://stocktwits.com/symbol/KVUE">Kenvue’s stock</a> has declined 17% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Kenvue company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Why Is Kenvue Stock Rising Premarket Today?

South Korea’s drug regulator said it will seek information from companies following U.S. claims about Tylenol and autism.

U.S. stocks retreated on Tuesday, snapping a three-session winning streak, as profit-taking in some of the tech stocks that had run up significantly generated selling pressure. Consumer discretionary and IT stocks primarily served as drags, although energy and real estate stocks recorded notable gains.After the market eased off its highs, the following stocks saw brisk trading activity in the extended session:Nvidia Corp. (NVDA)After-hours move: 0.28%Trading volume: 8.88 million<a href="https://stocktwits.com/symbol/NVDA">Nvidia’s stock</a> retreated 2.82% to $178.43 on Tuesday, following its nearly 4% rally in the previous session, which was driven by an announcement regarding a potential investment of up to $100 billion in artificial intelligence (AI) startup OpenAI.&nbsp;The retreat came amid profit-taking, as traders weighed in on Nvidia’s investments. On Tuesday, DA Davidson analyst Gil Luria expressed concerns that Nvidia could become an “investor of last resort,” bailing out CoreWeave, Intel, and now OpenAI, according to excerpts of the note made available by Fly.The analyst said he would have preferred more traditional investors to step up and fund the data center buildout.On Stocktwits, retail sentiment toward Nvidia stock remained ‘bullish’ as of late Tuesday, with message volume, however, at ‘normal’ levels.The stock has gained nearly 33% this year.Plug Power (PLUG)After-hours move: -4.74%Trading volume: 11.61 millionAfter declining 4.5% in Tuesday’s regular session,&nbsp;<a href="https://stocktwits.com/symbol/PLUG">Plug Power stock</a> fell sharply yet again in the after-hours. The stock initially jumped on Tuesday morning as the hydrogen fuel cell energy company’s announcement regarding hosting Oppenheimer at its Georgia plant excited investors. Alongside the announcement, the company stated that the facility achieved a record August performance, producing 324 metric tons of green hydrogen.The upward momentum could not be sustained as a nine-session winning streak in the stock prompted some traders to take profits.Retail sentiment toward Plug Power stock continues to remain ‘extremely bullish’ (92/100), and the message volume was ‘extremely high.’For the year-to-date period, the stock has increased by approximately 19%.Micron Technology, Inc. (MU)After-hours move: +0.44%Trading volume: 11.83 millionMemory chipmaker Micron reported&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/micron-stock-hardly-budges-after-ai-fueled-q4-beat/chDKV1YR3dI">forecast-beating results</a> for the fourth quarter of the fiscal year 2025, and issued upbeat guidance for the current quarter. The stock showed a muted reaction to the strong print.<a href="https://stocktwits.com/symbol/MU">Micron stock</a>, which has nearly doubled this year, elicited ‘extremely bullish’ sentiment (93/100) from among the retail users of Stocktwits. The message volume on the stream was also ‘extremely high.’Kenvue, Inc. (KVUE)After-hours move: +0.95%Trading volume: 7.17 millionKenvue remained on traders’ radar as the company’s stock rebounded from its all-time low. The stock came under pressure on Tuesday after President Donald Trump crusaded against the company’s best-selling iconic brand Tylenol, alleging that it caused autism and urging pregnant&nbsp;women not to consume it.With the medical and scientific community refuting the allegations and Wall Street firms estimating that the company would experience no severe impact from the entire episode, the stock rebounded by over 1.5% on Tuesday.&nbsp;Stocktwits retail traders’ sentiment tempered slightly to ‘bullish’ (61/100) as of late Tuesday from the ‘extremely bullish’ mood seen a day ago. The message volume continued to stay ‘extremely high.<a href="https://stocktwits.com/symbol/KVUE">Kenvue stock&nbsp;</a>has lost about 17% YTD.Kroger Co. (KR)After-hours move: unchangedTrading volume: 5.43 millionRetailer and supermarket operator Kroger (KR) saw its stock rise 1.29% on Tuesday despite the broader market pullback.&nbsp;<a href="https://stocktwits.com/symbol/KR">Kroger’s stock</a> has gained 8.5% so far this year. Last week, Argus increased its price target for Kroger stock by $1 to $85, citing the retailer’s innovative and increasingly affordable brands, strong private brands, growing emphasis on fresh food, and its strong customer analytics that help deliver personalized discounts to customers, according to The Fly.Retail sentiment toward the stock turned to ‘neutral’ (50/100) by late Tuesday from ‘bearish’ a day ago, while the message volume stayed at ‘low’ levels.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-lithium-americas-stock-jump-after-hours-today/chDKnOJR3dB">Why Did Lithium Americas Stock Jump After-Hours Today?</a>

Traders work on the floor of the New York Stock Exchange (NYSE) on September 03, 2025, in New York City. 

Nvidia, Plug Power, Micron, Kenvue, Kroger: What Sparked Heavy After-Hours Trading In These 5 Stocks?

Micron stock showed a muted reaction to earnings despite the quarterly numbers and guidance exceeding expectations.

U.S. President Donald Trump’s caution against Tylenol has reignited scrutiny of Kenvue, just as the U.S. FDA moves to add pregnancy-related autism warnings to acetaminophen labels and has alerted physicians nationwide.&nbsp;Although the agency acknowledged that no causal link has been established, plaintiffs’ lawyers say the new language could revive litigation dismissed by a federal court last December, according to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-23/tylenol-maker-kenvue-faces-mounting-crisis-after-trump-s-rebuke">report</a>.&nbsp;The heightened risk comes as Kenvue, under interim CEO Kirk Perry, faces weak sales, activist investor demands, and a portfolio review. Tylenol, its largest brand, contributes a mid- to high-single-digit share of revenue.&nbsp;Despite the legal overhang, Kenvue’s stock shrugged off concerns, rising 1.6% in regular trade and another 0.8% after hours on Tuesday. Investors took comfort in the fact that the FDA stopped short of a ban and that no new scientific evidence was presented.&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-kenvue-stock-rising-today/chDhDbOR350">Citigroup said it sees limited legal risk</a> and expects shares to trade higher, while Evercore ISI cut its price target to $18. Barclays argued that the recent selloff looks overdone, even under highly unlikely worst-case scenarios.The move may also mark Kenvue’s biggest reputational test since the 1980s Tylenol cyanide poisonings, with concerns&nbsp;that it could create confusion for patients who need to treat fevers during pregnancy.Plaintiffs’ lawyer Mark Lanier said the FDA move breathes new life into lawsuits, while legal experts noted courts rarely overturn the agency’s risk assessments. Kenvue stated that the claims lack both legal and scientific merit. Johns Hopkins professor Stacey Lee said even without proving causality, the label could be powerful evidence before juries.The company has been unsettled since its 2023 spin-off from Johnson &amp; Johnson. Former CEO Thibaut Mongon struggled to stabilize operations, prompting pressure from activist hedge funds Starboard Value, TOMS Capital, and Third Point. Kenvue responded by naming Perry interim CEO, adding Starboard’s Jeffrey Smith to its board, and&nbsp;considering the sale&nbsp;of smaller skincare brands, such as Neutrogena.The business faces a&nbsp;challenging consumer backdrop of inflation, high interest rates, and weaker demand, which has led to two consecutive quarters of declining organic sales and a reduction to its full-year forecast.&nbsp;On Stocktwits, retail sentiment for Kenvue was ‘bullish’ amid a 270% surge in 24-hour message volume.One user pointed out that no direct causal link between pregnancy and autism has been established and described the stock as a “huge buying opportunity,” adding that they bought shares after hours and expect it to soon reach $21.<stembedurl>https://stocktwits.com/Mukulu2025/message/629750922</stembedurl>Another bullish user called Kenvue a “great investment opportunity.”<stembedurl>https://stocktwits.com/Little_thebodyguard/message/629750599</stembedurl><a href="https://stocktwits.com/symbol/KVUE">Kenvue’s stock</a> has declined 17% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tylenol, which contains acetaminophen, is offered for sale at a drug store on April 14, 2015 in Chicago, Illinois. (Photo by Scott Olson/Getty Images)

Trump’s Tylenol Warning Sparks FDA Action, But Kenvue Stock Climbs: Retail Traders See ‘Huge Buying Opportunity’

Kenvue is facing renewed litigation risks, activist investor pressure, and a challenging consumer backdrop as it undertakes a portfolio review under interim CEO Kirk Perry.

Kenvue (KVUE) shares jumped nearly 4% in early trading on Tuesday and became the top trending ticker on Stocktwits after Citigroup stated that it sees limited legal risk for the company following President Donald Trump's discouragement of pregnant women from taking Acetaminophen, the active ingredient in Tylenol.Citi maintained a ‘Neutral rating on the stock with a $20 price target, according to TheFly. Citi expects Kenvue shares to trade higher on Tuesday, following yesterday's selloff, given the lack of new scientific evidence presented by the Trump administration regarding Tylenol use.The firm stated, however, that there could be a risk associated with Tylenol consumption due to the negative headlines.Retail sentiment on <a href="https://stocktwits.com/symbol/KVUE">Kenvue</a> jumped to ‘extremely bullish’ from ‘neutral’ territory a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits. The retail user message count on the stock increased by 1,860% in the last 24 hours on Stocktwits, as of Tuesday morning.Evercore ISI lowered the firm's price target on Kenvue to $18 from $23 and maintained an ‘In Line’ rating after FDA commissioner Marty Makary announced the start of a process to change the safety label on Acetaminophen. This is to suggest a potential link between its use and an increased risk of neurological conditions such as autism. Barclays analyst Lauren Lieberman noted that the Trump administration's views on the links between Tylenol and autism are contrary to the mainstream medical establishment. The firm's "rough math" suggests that Kenvue's 17% selloff since September 4 is overdone, even in the "highly-unlikely scenario" that its U.S. Acetaminophen business is reduced to zero.Shares of Kenvue have declined nearly 24% in the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/amazon-to-close-its-amazon-fresh-uk-stores/chDhwyFR35L">Amazon To Close Its ‘Amazon Fresh UK’ Stores</a>

Why Is Kenvue Stock Rising Today?

Citi noted that Kenvue shares would be trading higher on Tuesday following yesterday's selloff, given the lack of new scientific evidence presented by the Trump administration regarding Tylenol use.

Tylenol manufacturer Kenvue, Inc.‘s (KVUE) battered stock appears on track to rebound from Monday’s ravages inflicted by President Donald Trump's suggestion at a White House press conference that the usage of the iconic brand causes autism.The president said Tylenol "is no good" and that pregnant women should "fight like hell" only to take it in cases of extreme fever.<a href="https://stocktwits.com/symbol/KVUE">Kennvue stock,</a> which fell 7.47% on Monday to a record low, was last seen rising nearly 6% in premarket trading. The rebound comes after the company, a spin-off of Johnson &amp; Johnson, and experts refuted Trump’s claims.&nbsp;The company reportedly&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.axios.com/2025/09/22/trump-tylenol-autism-announcement-kenvue">said</a> in a statement that “acetaminophen is the safest pain reliever option for pregnant women as needed throughout their entire pregnancy.” Acetaminophen&nbsp;is the base ingredient for Tylenol.“We believe independent, sound science clearly shows that taking acetaminophen does not cause autism. We strongly disagree with any suggestion otherwise and are deeply concerned with the health risk this poses for&nbsp;expectant mothers."A separate Reuters report&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/tylenol-maker-kenvue-shares-bounce-trump-claims-face-pushback-2025-09-23/">stated</a> that Citi analysts expected the stock to recover from the sell-off on Monday. “Overall, we see limited judicial risk following today's announcement, but there could be some impact on Tylenol consumption due to negative headlines,” they said.This should alleviate investor concerns about the company facing a barrage of lawsuits over the alleged adverse effects of Tylenol.The report also noted that many doctors disagreed with the Trump administration’s Tylenol claims and warned that these unfounded claims&nbsp;would likely impair maternal health.Eric Liang Feigl-Ding, an American public health scientist, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrEricDing/status/1970238664169885774">said </a>on X that "RFK Jr and Trump are wrong—the largest &amp; best study in the world in 2.5 MILLION KIDS—found no increased autism risk with acetaminophen (aka paracetamol, Tylenol) use by the mother during pregnancy.""A crude unadjusted analysis found only a preliminary 5% risk, but once you adjust for family by matching using sibling controls (who didn’t get autism), the even tiny 5% risk vaporizes to 0%."On Stocktwits, retail sentiment toward Kenvue stock flipped to 'extremely bullish' (92/100) by early Tuesday from 'bearish' a day ago, and the message volume was 'extremely high.'<figure class="image"><img style="aspect-ratio:628/57;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_23_at_5_59_12_AM_png_e85794a3af.webp" alt="Screenshot 2025-09-23 at 5.59.12 AM.png" width="628" height="57"><figcaption>KVUE sentiment and message volume as of 6 a.m. ET, Sept. 23 | source: Stocktwits</figcaption></figure>Kenvue stock is down more than 21% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:<a href="https://stocktwits.com/news-articles/markets/equity/applied-materials-gets-price-target-boost-while-analyst-turns-cautious-on-lam-research/chDhqaKR3PD"> Applied Materials Stock Gets Price-Target Boost While Analyst Turns Cautious On Lam Research: Here’s Why</a>

In this photo illustration, a Tylenol caplet is displayed on September 22, 2025, in San Anselmo, California. 

Kenvue On Track To Bounce Back From Record Lows — What’s Driving Stock Higher In Premarket?

Many doctors reportedly disagreed with the Trump administration’s Tylenol claims and warned that these unfounded claims would likely impair maternal health.

Shares of Johnson &amp; Johnson held up better than its consumer spinoff, Kenvue, on Monday after U.S. President Donald Trump linked autism to Tylenol and childhood vaccines, claims that decades of scientific research have not supported.&nbsp;J&amp;J shares slipped 1.1% to $174.21 in regular trade before gaining 0.5% after hours. Meanwhile, Kenvue fell 7.5% to a record low at $16.97 before rebounding 4.4% in late trading.&nbsp;Guggenheim upgraded J&amp;J to ‘Buy’ from ‘Neutral’ with a raised price target of $206 from $167, which implies an upside of 18% from J&amp;J’s closing price on Monday.&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kenvue-stock-hits-record-low-trump-urges-pregnant-women-fight-like-hell-against-tyleno/chDhg0tR3PR">Trump’s sharp warnings against acetaminophen</a>, the active ingredient in Tylenol, directly pressured Kenvue, while J&amp;J moved lower more modestly, supported by its diversified portfolio and pipeline updates.Johnson &amp; Johnson has also remained a defensive play for income investors. The company went ex-dividend on Aug. 26, with its most recent quarterly payout made on Sept. 9, underscoring its steady record of shareholder returns even as sector peers face volatility.Earlier this month, Josh Brown, CEO of Ritholtz Wealth Management, told&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/video/2025/09/16/josh-browns-best-stocks-in-the-market-johnson-johnson.html">CNBC</a> that J&amp;J’s transformation into a pure-play healthcare company after spinning off Kenvue, coupled with a pipeline focused on oncology, immunology, neuroscience, and medtech, is helping steady sentiment. He noted the stock has been “building a base” for years and could be on the verge of a breakout if it clears long-term resistance.The company also drew attention in the U.S. Psychiatric and Mental Health Congress, where it released Phase 3 data for its investigational depression treatment seltorexant on Monday. The trial showed the drug has efficacy similar to that of quetiapine XR, a frequently used adjunctive therapy, but was well-tolerated with&nbsp;fewer adverse events like drowsiness and weight gain.&nbsp;While it did not hit its primary target, seltorexant was still better tolerated as measured by a higher completion rate at week 26, supporting its use in patients with major depressive disorder who are still suffering from insomnia symptoms.On Friday, J&amp;J also said the FDA approved a subcutaneous induction regimen of Tremfya for adults with ulcerative colitis, making it the first IL-23 inhibitor to offer both SC and IV induction options for UC and Crohn’s disease, which&nbsp;affects about 3 million Americans.&nbsp;On Stocktwits, retail sentiment&nbsp;for JNJ,&nbsp;however, was ‘extremely bearish’ amid&nbsp;a 1,720% spike in 24-hour message volume. One user said J&amp;J could still face billions in liability from Tylenol autism suits despite Kenvue assuming primary responsibility after the 2023 spin-off, especially when combined with ongoing talc cases.&nbsp;<stembedurl>https://stocktwits.com/StormChaser/message/629585491</stembedurl>Another&nbsp;user jokingly remarked that with more than 66,000 talc plaintiffs and fresh Tylenol claims, J&amp;J might soon “own the largest law firm in the world.”<stembedurl>https://stocktwits.com/Suite510/message/629583920</stembedurl><a href="https://stocktwits.com/symbol/JNJ">Johnson &amp; Johnson’s stock</a> has risen 23.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 Johnson and Johnson American multinational of medical, pharmaceutical and perfumery products headquartes on 28 January 2025 in Madrid, Spain.

Johnson & Johnson Stock Weathers Trump’s Tylenol Attacks Better Than Kenvue Amid Dipping Retail Confidence — What’s Holding Losses in Check?

Guggenheim’s upgrade and new data on J&J’s experimental depression drug helped steady sentiment, even as investors weighed political scrutiny and ongoing litigation risks.

U.S. President Donald Trump on Monday linked autism to both childhood vaccines and the use of Tylenol by pregnant women and children, claims that decades of scientific research have not supported.&nbsp;Meanwhile, Kenvue, the maker of Tylenol, rejected the claims. “We believe independent, sound science clearly shows that taking acetaminophen does not cause autism. We strongly disagree with any suggestion otherwise and are deeply concerned with the health risk this poses for expecting mothers,” according to a Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/trump-expected-link-autism-with-tylenol-experts-say-more-research-needed-2025-09-22/">report</a>, citing a company statement.&nbsp;Kenvue, which was spun off from Johnson &amp; Johnson in 2023, saw its shares fall 7.5% during Monday’s session to a record low before recovering 4.4% in extended trading.In a White House news conference, Trump repeatedly advised women and parents not to use the painkiller, saying, “Don’t take Tylenol. Fight like hell not to take it,” while acknowledging he was not a doctor.Standing alongside Health Secretary Robert F. Kennedy Jr., a longtime vaccine critic, Trump also called for a reexamination of vaccine schedules, urging separate measles, mumps, and rubella shots, and stating that the hepatitis B vaccine should not be administered until age 12, despite longstanding medical guidance recommending it within 24 hours of birth.&nbsp;Tylenol is Kenvue's largest brand, accounting for a mid-to-high single-digit percentage of total sales, The Wall Street Journal&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/healthcare/trump-autism-report-announcement-eb7c90c8?mod=hp_lead_pos1">noted</a>, citing Morningstar. Trump’s warning also comes as Kenvue continues to face litigation over acetaminophen, with hundreds of lawsuits alleging a link to autism or ADHD currently under appeal after a federal judge last year ruled the scientific evidence unreliable.Meanwhile, acetaminophen remains an important option for pregnant women, and vaccines have saved millions of lives, with UNICEF estimating at least 154 million lives preserved over the last 50 years.The Trump administration also announced steps to position leucovorin, a form of folic acid currently used in chemotherapy support, as a treatment for autism-related symptoms.&nbsp;The FDA approved a version of the drug from GSK and cited a review of 40 patients with cerebral folate deficiency, a rare metabolic disorder linked to neurological symptoms. Medicaid coverage for leucovorin will be extended to autism patients, with expectations that private insurers will follow.Researchers reiterated that there is no solid evidence that acetaminophen causes autism. A 2024 study using 2.5 million Swedish children found no causal relationship. In 2025, a review of 46 previous studies was done, which found an association, but it does not show cause and effect.&nbsp;Researchers advised that pregnant women who need acetaminophen should continue taking it at the lowest dose and for the shortest time. Bigger, randomized trials are still needed to determine leucovorin's potential.On Stocktwits, retail sentiment for Kenvue was ‘extremely bullish’ amid ‘extremely high’ message volume.One bullish user said the administration’s comments unfairly singled out Kenvue as if Tylenol were the only acetaminophen brand on the market, adding that people weren’t about to stop using the drug for everyday needs and calling the concerns overblown.<stembedurl>https://stocktwits.com/FatherofTrades/message/629593979</stembedurl>Another user said that they were buying every dip in Kenvue shares and planned to hold through the lawsuits and any eventual settlement.<stembedurl>https://stocktwits.com/StockCapture/message/629592908</stembedurl><a href="https://stocktwits.com/symbol/KVUE">Kenvue’s stock</a> has declined 18.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Kenvue Stock Hits Record Low As Trump Urges Pregnant Women To ‘Fight Like Hell’ Against Tylenol: Retail Stays Bullish

Investors weighed political scrutiny and unproven health claims as Tylenol’s maker faced renewed controversy, sparking volatility in Kenvue’s stock.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

KVUE
Kenvue Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest KVUE News

KVUEKenvue Inc